Dr. rer. nat. Thomas Müller

Magnifier Icon Suche
  • Diplom-Biochemiker 
  • Leiter AG Experimentelle Onkologie
  • Projektleiter nach § 3 Nr. 8 Gentechnikgesetz
  • Mechanismen der Chemotherapieresistenz von Tumoren und Möglichkeiten zur Überwindung
  • Charakterisierung neuer Wirkstoffe und präklinische Validierung von Substanz- und Vehikel-basierender Therapie
  • In-vivo-Imaging basierte Untersuchungen zur Biologie und Therapie von Tumoren


Noack AK, Lucas H, Chytil P, Etrych T, Mader K, and Mueller T: Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment. Int J Mol Sci2020;21: 6029.



Mueller T, Freystein J, Lucas H, and Schmoll HJ: Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules2019;24: 2865.

Schmitt F, Gold M, Rothemund M, Andronache I, Biersack B, Schobert R, and Mueller T: New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. Eur J Med Chem2019;163: 160-8.

Steinemann G, Dittmer A, Schmidt J, Josuttis D, Fahling M, Biersack B, Beindorff N, Jolante Koziolek E, Schobert R, Brenner W, Muller T, Nitzsche B, and Hopfner M: Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. Mol Oncol2019;13: 2679-96.

Schmitt F, Gosch LC, Dittmer A, Rothemund M, Mueller T, Schobert R, Biersack B, Volkamer A, and Hopfner M: Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure(-)Activity Relations of New Inhibitors of HDAC and/or Tubulin Function. Int J Mol Sci2019;20: 383.

Werner S, Lutzkendorf J, Muller T, Muller LP, and Posern G: MRTF-A controls myofibroblastic differentiation of human multipotent stromal cells and their tumour-supporting function in xenograft models. Sci Rep2019;9: 11725.



Mueller T, Hantsch C, Volkmer I, and Staege MS: Differentiation-Dependent Regulation of Human Endogenous Retrovirus K Sequences and Neighboring Genes in Germ Cell Tumor Cells. Front Microbiol2018;9: 1253.

Weiss VM, Lucas H, Mueller T, Chytil P, Etrych T, Naolou T, Kressler J, and Mader K: Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. Macromol Biosci2018;18: 1.



Mueller T, Pfankuchen DB, Wantoch von Rekowski K, Schlesinger M, Reipsch F, and Bendas G: The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models. Molecules 2017;22: 728.

Schaffrath J, Schmoll HJ, Voigt W, Muller LP, Muller-Tidow C, and Mueller T: Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One 2017;12: e0178930.

Bahr I, Goritz V, Doberstein H, Hiller GG, Rosenstock P, Jahn J, Portner O, Berreis T, Mueller T, Spielmann J, and Kielstein H: Diet-Induced Obesity Is Associated with an Impaired NK Cell Function and an Increased Colon Cancer Incidence. J Nutr Metab 2017;2017: 4297025.



Schmitt F, Donnelly K, Muenzner JK, Rehm T, Novohradsky V, Brabec V, Kasparkova J, Albrecht M, Schobert R, and Mueller T: Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. J Inorg Biochem 2016;163: 221-8.

Heinrich AK, Lucas H, Schindler L, Chytil P, Etrych T, Mader K, and Mueller T: Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. Mol Cancer Ther 2016;15: 998-1007.

Studenovský M, Heinrich AK, Lucas H, Mueller T, Mader K, and Etrych T: Dual fluorescent N-(2-hydroxypropyl) methacrylamide-based conjugates for passive tumor targeting with reduction-sensitive drug release: Proof of the concept, tumor accumulation, and biodistribution. J Bioact Compat Polym 2016;31: 348-60.

Pola R, Heinrich AK, Mueller T, Kostka L, Mader K, Pechar M, and Etrych T: Passive Tumor Targeting of Polymer Therapeutics: In Vivo Imaging of Both the Polymer Carrier and the Enzymatically Cleavable Drug Model. Macromol Biosci 2016;16: 1577-82.

Mahal K, Biersack B, Schruefer S, Resch M, Ficner R, Schobert R, and Mueller T: Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. Eur J Med Chem 2016;118: 9-20.

Lomkova EA, Chytil P, Janouskova O, Mueller T, Lucas H, Filippov SK, Trhlikova O, Aleshunin PA, Skorik YA, Ulbrich K, and Etrych T: Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting. Biomacromolecules 2016;17: 3493-507.

Etrych T, Lucas H, Janouskova O, Chytil P, Mueller T, and Mader K: Fluorescence optical imaging in anticancer drug delivery. J Control Release 2016;226: 168-81.

Widder M, Lutzkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Muller-Tidow C, Muller T, and Muller LP: Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a beta1-integrin-dependent mechanism. Int J Cancer 2016;138: 964-75.

Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JV, and Paschke R: In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and invivo safety assessment of the compound NVX-207 in two horses. Chem Biol Interact 2016;246: 20-9.



Mahal K, Biersack B, Caysa H, Schobert R, and Mueller T: Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Invest New Drugs 2015;33: 541-54.

Kurze C, Le Conte Y, Dussaubat C, Erler S, Kryger P, Lewkowski O, Muller T, Widder M, and Moritz RF: Nosema Tolerant Honeybees (Apis mellifera) Escape Parasitic Manipulation of Apoptosis. PLoS One 2015;10: e0140174.

Belete A, Metz H, Mueller T, and Maeder K: Benchtop MRI for pharmacokinetic evaluation of two aqueous-based nano-scaled formulations of oleic acid stabilized magnetite nanocrystals. Drug Dev Ind Pharm 2015;41: 406-14.



Mahal K, Resch M, Ficner R, Schobert R, Biersack B, and Mueller T: Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem 2014;9: 847-54.



Rizzello CG, Mueller T, Coda R, Reipsch F, Nionelli L, Curiel JA, and Gobbetti M: Synthesis of 2-methoxy benzoquinone and 2,6-dimethoxybenzoquinone by selected lactic acid bacteria during sourdough fermentation of wheat germ. Microb Cell Fact 2013;12: 105.

Hoffmann S, Caysa H, Kuntsche J, Kreideweiss P, Leimert A, Mueller T, and Mader K: Carbohydrate plasma expanders for passive tumor targeting: in vitro and in vivo studies. Carbohydr Polym 2013;95: 404-13.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, and van der Kuip H: Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res 2013;73: 1460-9.

Chytil P, Hoffmann S, Schindler L, Kostka L, Ulbrich K, Caysa H, Mueller T, Mader K, and Etrych T: Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J Control Release 2013;172: 504-12.



Schadlich A, Hoffmann S, Mueller T, Caysa H, Rose C, Gopferich A, Li J, Kuntsche J, and Mader K: Accumulation of nanocarriers in the ovary: a neglected toxicity risk? J Control Release 2012;160: 105-12.

Kaps L, Biersack B, Muller-Bunz H, Mahal K, Munzner J, Tacke M, Mueller T, and Schobert R: Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. J Inorg Biochem 2012;106: 52-8.

Kaluderovic GN, Dietrich A, Kommera H, Kuntsche J, Mader K, Mueller T, and Paschke R: Liposomes as vehicles for water insoluble platinum-based potential drug: 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum( II). Eur J Med Chem 2012;54: 567-72.

Hoffmann S, Vystrcilova L, Ulbrich K, Etrych T, Caysa H, Mueller T, and Mader K: Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging. Biomacromolecules 2012;13: 652-63.

Caysa H, Hoffmann S, Luetzkendorf J, Mueller LP, Unverzagt S, Mader K, and Mueller T: Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging. PLoS One 2012;7: e47927.



Schobert R, Seibt S, Mahal K, Ahmad A, Biersack B, Effenberger-Neidnicht K, Padhye S, Sarkar FH, and Mueller T: Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M. J Med Chem 2011;54: 6177-82.

Schadlich A, Rose C, Kuntsche J, Caysa H, Mueller T, Gopferich A, and Mader K: How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 2011;28: 1995-2007.

Schadlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Gopferich A, Kuntsche J, and Mader K: Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano 2011;5: 8710-20.

Mueller T, and Voigt W: Fermented wheat germ extract--nutritional supplement or anticancer drug? Nutr J 2011;10: 89.

Mueller T, Jordan K, and Voigt W: Promising cytotoxic activity profile of fermented wheat germ extract (Avemar(R)) in human cancer cell lines. J Exp Clin Cancer Res 2011;30: 42.

Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, and Mueller T: TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011;18: 229-39.

Caysa H, Metz H, Mader K, and Mueller T: Application of Benchtop-magnetic resonance imaging in a nude mouse tumor model. J Exp Clin Cancer Res 2011;30: 69.

Biersack B, Dietrich A, Zoldakova M, Kalinowski B, Paschke R, Schobert R, and Mueller T: Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells. J Inorg Biochem 2011;105: 1630-7.

Besheer A, Caysa H, Metz H, Mueller T, Kressler J, and Mader K: Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES). Int J Pharm 2011;417: 196-203.



Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, and Mueller T: 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J Med Chem 2010;53: 6595-602.

Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, and Schmoll HJ: Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochem Cell Biol 2010;134: 197-204.

Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, and Schmoll HJ: Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010;14: 2292-304.

Kommera H, Kaluderovic GN, Dittrich S, Kalbitz J, Drager B, Mueller T, and Paschke R: Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity. Bioorg Med Chem Lett 2010;20: 3409-12.

Eisenmann S, Voigt W, Muller T, and Dempke W: Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro. Anticancer Res 2010;30: 4471-6.



Schobert R, Biersack B, Dietrich A, Knauer S, Zoldakova M, Fruehauf A, and Mueller T: Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. J Med Chem 2009;52: 241-6.

Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, and Mueller LP: Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. Cell Mol Life Sci 2009;66: 495-503.

Dansranjavin T, Krehl S, Mueller T, Mueller LP, Schmoll HJ, and Dammann RH: The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. Cell Cycle 2009;8: 916-24.



Kelly ME, Dietrich A, Gomez-Ruiz S, Kalinowski B, Kaluderović GN, Müller T, Paschke R, Schmidt J, Steinborn D, Wagner C, and Schmidt H: Platinum(IV) metallacrown ethers: Synthesis, structures, host properties and anticancer evaluation. Organometallics 2008;27: 4917-27.

Kaluderović GN, Schmidt H, Schwieger S, Wagner C, Paschke R, Dietrich A, Mueller T, and Steinborn D: Platinum(IV) complexes with ethylenediamine-N,N '-diacetate diester (R(2)edda) ligands: Synthesis, characterization and in vitro antitumoral activity. Inorganica Chimica Acta 2008;361: 1395-404.

Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A, Schmoll HJ, Kloft C, and Voigt W: 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum( II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin. J Med Chem 2008;51: 5413-22.



Schobert R, Biersack B, Dietrich A, Grotemeier A, Müller T, Kalinowski B, Knauer S, Voigt W, and Paschke R: Monoterpenes as drug shuttles: cytotoxic (6-aminomethylnicotinate)dichloridoplatinum(II) complexes with potential to overcome cisplatin resistance. J Med Chem 2007;50: 1288-93.

Kaluderović GN, Schmidt H, Paschke R, Kalinowski B, Dietrich A, Mueller T, and Steinborn D: Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity. J Inorg Biochem 2007;101: 543-9.



Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, and Schmoll HJ: Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol 2006;27: 71-83.

Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, and Schmoll HJ: Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006;24: 2753-65.



Voigt W, Pickan V, Pfeiffer C, Mueller T, Simon H, and Arnold D: Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. Onkologie 2005;28: 482-8.

Voigt W, Kegel T, Weiss M, Mueller T, Simon H, and Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005;131: 585-90.

Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, and Dempke W: Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Anticancer Res 2005;25: 1147-55.


2004 - 1999

Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, and Sinn E: Biomolecules linked to transition metal complexes--new chances for chemotherapy. Curr Med Chem 2003;10: 2033-44.

Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll HJ, Mueller H, Sorkau E, and Sinn E: Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J Inorg Biochem 2003;94: 335-42.

Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, and Schmoll HJ: Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003;63: 513-21.

Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C, and Schmoll HJ: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000;6: 2087-93.

Grothey A, Voigt W, Schöber C, Müller T, Dempke W, and Schmoll HJ: The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 1999;125: 166-73